fasudil has been researched along with Diabetes Mellitus, Type 1 in 5 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with fasudil or captopril suppressed not only the inflammation reaction but also the accumulation of the extracellular matrix due to the downregulation of TGF-β1 and MMP-9/TIMP-1, which induces the amelioration of the liver fibrosis with diabetes." | 1.48 | Fasudil alleviates hepatic fibrosis in type 1 diabetic rats: involvement of the inflammation and RhoA/ROCK pathway. ( Chu, L; Huo, M; Ma, ZH; Song, T; Wang, N; Xie, Y; Zhang, JP; Zhang, Y; Zhang, YY, 2018) |
| "The treatment with fasudil after the development of diabetes improved the metabolic abnormalities in OLETF rats, but could not suppress the progression of nephropathy." | 1.34 | A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. ( Higashi, K; Hyodo, N; Imakiire, T; Kikuchi, Y; Kushiyama, T; Miura, S; Oda, T; Suzuki, S; Yamada, M; Yamamoto, K, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xie, Y | 1 |
| Song, T | 1 |
| Huo, M | 1 |
| Zhang, Y | 1 |
| Zhang, YY | 1 |
| Ma, ZH | 1 |
| Wang, N | 1 |
| Zhang, JP | 1 |
| Chu, L | 1 |
| Waddingham, MT | 1 |
| Edgley, AJ | 1 |
| Astolfo, A | 1 |
| Inagaki, T | 1 |
| Fujii, Y | 1 |
| Du, CK | 1 |
| Zhan, DY | 1 |
| Tsuchimochi, H | 1 |
| Yagi, N | 1 |
| Kelly, DJ | 1 |
| Shirai, M | 1 |
| Pearson, JT | 1 |
| Nuno, DW | 1 |
| Lamping, KG | 1 |
| Biswas, PS | 1 |
| Gupta, S | 1 |
| Chang, E | 1 |
| Bhagat, G | 1 |
| Pernis, AB | 1 |
| Kikuchi, Y | 1 |
| Yamada, M | 1 |
| Imakiire, T | 1 |
| Kushiyama, T | 1 |
| Higashi, K | 1 |
| Hyodo, N | 1 |
| Yamamoto, K | 1 |
| Oda, T | 1 |
| Suzuki, S | 1 |
| Miura, S | 1 |
5 other studies available for fasudil and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Fasudil alleviates hepatic fibrosis in type 1 diabetic rats: involvement of the inflammation and RhoA/ROCK pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Diabetes Mellitus, Experimental; Diabetes Me | 2018 |
Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Diabetes Mellitus, Experimental; Dia | 2015 |
The role of rho kinase in sex-dependent vascular dysfunction in type 1 diabetes.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Diabetes Mellitus, Experimental; Diabetes Me | 2010 |
Aberrant ROCK activation promotes the development of type I diabetes in NOD mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; CD4-Positive T-Lymphocytes; Diabetes Mellitu | 2011 |
A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Glucose; Carrier Proteins; Diabetes Me | 2007 |